Thu, Aug 28, 2014, 1:06 PM EDT - U.S. Markets close in 2 hrs 54 mins


% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • scistats scistats Nov 6, 2013 12:07 AM Flag

    Convergence Cav2.2 blocker seeing "few adverse events"

    "At doses up to 300mg/kg, CNV2197944 showed no effect in the rotarod, on blood pressure or heart rate in the telemetered rat, demonstrating a significant TI. As a result, with 28day GLP tox confirming a favourable safety window, CNV2197944 was progressed to phase I single ascending dose study where it demonstrated dose proportional PK and very good tolerability. The multiple ascending dose study results are expected 2Q of 2012. These data suggest that CNV2197944 has the activity and developability properties consistent with being a first in class, oral, state-dependent, selective Cav2.2 blocker for the treatment of chronic pain."

    "Phase I, placebo-controlled, single and multiple ascending dose clinical studies with orally administered CNV2197944, demonstrated that the drug was well tolerated in all subjects, with FEW ADVERSE EVENTS reported at doses expected to fall within the predicted therapeutic range. CNV2197944 was well absorbed following oral administration, with a pharmacokinetic profile that is predictable and consistent in both young and elderly subjects. These characteristics indicate CNV2197944’s optimal profile for a chronic pain medication.

    We have recently initiated two, well powered Phase II proof of concept trials for CNV2197944 in neuropathic pain."

    Sentiment: Strong Buy

1.18+0.03(+2.61%)Jul 15 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.